Reduce dsRNA and optimize your IVT with our enhanced enzymes and high‑quality raw materials
WEBINAR
As regulatory expectations intensify, mRNA developers face stricter demands for impurity control, transparent documentation, and consistent raw‑material quality. Enzyme variability and elevated dsRNA reduce mRNA quality, impact safety and translation efficiency, and increase downstream purification burden.
In this insider session, we introduce our enhanced T7 RNA Polymerase and Inorganic Pyrophosphatase (IPP) Emprove® Expert— designed to deliver higher transcription yields, significantly reduced dsRNA formation, and consistent performance across batches. Combined with our high‑quality raw materials portfolio and supported by comprehensive Emprove® Dossiers, these solutions help de‑risk development, strengthen regulatory readiness, and enable reliable, high‑purity mRNA production from early process development through scale‑up.
In this webinar, you will learn:
- Understand why selecting raw materials suitable for pharmaceutical use from the start is essential for reliable, high‑quality mRNA manufacturing.
- Learn why dsRNA formation remains a key challenge in IVT and how new technologies can help reduce manufacturing complexity and downstream burden
- Discover how our enhanced T7 RNA Polymerase Emprove® Expert, and high‑quality raw materials improve transcription efficiency, reduce dsRNA, and deliver consistent performance.
Speaker List
Nelli Erwin, Ph.D.
Merck
Senior Manager, Head of Protein Stability
Nelli heads the protein stability laboratory in process and formulation materials - technology and innovation (T&I) at Merck. In this role, she is mainly responsible for the development of new technologies to improve the stability of biomolecule formulations. Her previous work experience includes a postdoc position in Analytical R&D at AbbVie. She holds a Ph.D. from the Technical University of Dortmund in Chemical Biology, investigating the structure and dynamics of biomolecules.
Oliver Prince, Ph.D.
Merck
Sr. Modality Expert for pDNA/mRNA, Process Solutions
Oliver Prince is the senior modality expert for pDNA/mRNA manufacturing within Merck. With more than a decade of experience as a scientist, he has also held roles in strategy and marketing servicing the life science community. In his current role, Oliver fosters innovation and growth through people engagement, identifying unmet needs, and monitoring trends in the pDNA/mRNA segment.
Pharma and biopharma manufacturing
- Solid Formulation Strategies
Duration:1h
Language:English
Session 1:presented May 28, 2026